JMSACL (Journal of Mass Spectrometry & Advances in the Clinical Lab)’s Post

🧬𝐍𝐞𝐰 𝐄𝐧𝐳𝐲𝐦𝐞, 𝐀𝐃𝐂, 𝐚𝐧𝐝 𝐦𝐀𝐛 𝐢𝐧 𝐒𝐭𝐨𝐜𝐤💊   We have newly stocked some crucial therapeutics for your research needs:   🧬 Avalglucosidase alfa (Nexviadyme®): A therapeutic enzyme for the treatment of Pompe disease, helping to reduce glycogen accumulation in the body.   💉 Brentuximab vedotin (Adcetris®): An antibody-drug conjugate (ADC) used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.   🧫 Elotuzumab (Empliciti®): A monoclonal antibody (mAb) used to treat multiple myeloma by targeting the SLAMF7 protein on myeloma cells.   🔬 Confidently navigate your research journey with the essential tools readily available in our stock. Get these and many more therapeutic molecules as lab consumables from the original drugs in our online shop (link in the comments). Discover global access, reliable sourcing, and research benefits!   #InnovationInMedicine #ResearchAndDevelopment #ClinicalGradeMolecules #Evidentic #Antibody #mAb #ClinicalGrade #DrugDevelopment #DrugDiscovery

The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market is projected to grow from USD 8.26 billion in 2021 to USD 12.14 billion by 2030 at a CAGR of 8.4% during the forecast period. To Know More: https://lnkd.in/gMCs9ed7 Non-lymphomas Hodgkin's are one of the most prevalent lymphomas, and thus one of the most common malignancies. It is potentially fatal if not treated adequately, and the patients diagnosed have a shortened life span. TakedaPharmaceutical Nordics AB, AstraZeneca, Bayer, Novartis, Spectrum Pharmaceuticals, Inc., Teva Pharmaceuticals, Bristol Myers Squibb, Janssen Pharmaceuticals, Inc., Genentech and Merck & Co., Inc. #nhl #lymphoma #cancertreatment #oncology #immunotherapy #chemotherapy #targetedtherapy #biologictherapy #hematology #precisionmedicine #cartcelltherapy #monoclonalantibodies

BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy Proper Name: lisocabtagene maraleucel Manufacturer: Juno Therapeutics, Inc. (https://lnkd.in/gWrpWAH8), a Bristol-Myers Squibb Indication: - Adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B - Adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. <---- ACTUAL ACCELERATED APPROVAL BY FDA - Adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy. Efficacy was evaluated in TRANSCEND-FL (NCT04245839: https://lnkd.in/gcpzdRAr), a Phase 2, open-label, multicenter, single-arm trial in adults with relapsed or refractory FL after two or more lines of systemic therapy (including an anti-CD20 antibody and an alkylating agent). The main efficacy outcome measures were overall response rate (ORR), defined as the percentage of patients with a best overall response (BOR) of complete response or partial response after lisocabtagene maraleucel infusion, and duration of response (DOR) as determined by an independent review committee. The ORR was 95.7% (95% CI: 89.5, 98.8). After a median follow up of 16.8 months (95% CI: 16.3, 17.0), the median DOR was not reached (NR) (95% CI: 18.04, NR). Breyanzi FDA accelerated approval: https://lnkd.in/gJA2RUZb

CelluSPOT Synthese im Peptidsynthesizer MultiPep 2 Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers https://lnkd.in/eGFnuFwJ #Peptode #peptide #peptidsynthesizer #peptidesynthesis #CelluSPOT #Multipep #CEM #Intavis

Source: European journal of haematology This study developed and validated a method for quantifying midostaurin in plasma and serum using liquid chromatography-tandem mass spectrometry. The method was applied to a cohort of patients with acute myeloid leukemia (AML) receiving midostaurin treatment. The results showed high interindividual variability in midostaurin serum concentrations, indicating the need for personalized dosage approaches in AML patients. Further studies and standardization of analytical methods are necessary to support this approach.

Innate Pharma reports its first quarter 2024 business update and financial results 📊 ➡️ First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024 ➡️ Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 to Phase 2 in blood cancers ➡️ Five ASCO Annual Meeting 2024 abstracts: - Final TELLOMAK Phase 2 data for lacutamab in Mycosis Fungoides - Two posters on IPH6501, Innate's second generation ANKET® in B-cell Non-Hodgkin's Lymphoma - AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial - Monalizumab SCLC Phase 2 MOZART trial poster ➡️ Cash position of €113.9 million as of March 31, 2024 (not including the €4.0 million payment to be received from Sanofi), anticipated cash runway into end 2025 👨💻 Reminder, the conference call to be held today at 2:00 p.m. CEST / 8:00 a.m EDT : https://lnkd.in/eb-epmWZ More info 👉 https://lnkd.in/d7-jx9b8 #InnatePharma #BusinessUpdate #FinancialResults

Antibody-drug conjugates (ADCs) represent a promising approach to cancer treatment, facilitating the targeted delivery of potent cytotoxic payloads directly to tumors. ADCs consist of a monoclonal antibody and a highly cytotoxic payload linked by a chemical linker. ADCs combine the target specificity and extended circulation half-life of antibodies with the potent anti-tumor properties of cytotoxic agents that may be too toxic for independent administration. This innovative molecular design holds significant potential in enhancing the efficacy and safety of cancer therapies. https://lnkd.in/eNf7S-S6

CelluSPOT Synthese im Peptidsynthesizer MultiPep 2 Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers https://lnkd.in/euSWUk8p #Peptode #peptide #peptidsynthesizer #peptidesynthesis #CelluSPOT #Multipep #CEM #Intavis  

This paper suggests that a novel CEACAM6-targeted antibody–drug conjugate (ADC) named EBET for PDAC therapy. CEACAM6-EBET ADC delivers BET protein degrader via CEACAM6 antibody, Modulation of PDAC Stromal : Bystander efficacy on CEACAM6-negative Cancer-Associated Fibroblasts (CAFs) inhibits STAT3 signaling, contributing to break down of the PDAC stromal. Authors say that this dual impact on PDAC cells and stroma is a key feature. https://lnkd.in/g43BaqPm

I have been curious about this for a very long time: in terms of clinical efficacy, which is better, chimeric antigen receptor T (CAR-T) cells vs bispecific monoclonal antibodies (BiAbs)? In the case of triple-class refractory myeloma, this work reported that CAR-T therapy resulted in better overall survival (OS), but there is no clinical significance in progression-free survival (PFS). https://lnkd.in/gQWRzpuY